Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it ...

Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.

Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the ...

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key ...

Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly ...

AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said.

Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of ...

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a ...